In the News
An archive of news items pertaining to
Pulmonary Fibrosis, Hypersensitivity Pneumonitis and Interstitial Lung Disease.
Pulmonary Fibrosis in the News
PFF program to aid people with new pulmonary fibrosis diagnosis
by Esteban Dominguez Cerezo | November 22, 2024
The Pulmonary Fibrosis Foundation (PFF) has launched “PF Basics: Info for Newly Diagnosed Patients,” a new educational program to help patients...
Phase 1b trial launched of inhaled nintedanib for pulmonary fibrosis
by Andrea Lobo | August 23, 2024
Avalyn Pharma has initiated a Phase 1b clinical trial to test AP02, a therapeutic candidate
for pulmonary fibrosis (PF), in adult healthy volunteers...
IPF treatment AGMB-447 granted FDA orphan drug status
by Andrea Lobo | June 21, 2024
AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (IPF) now being tested in a Phase 1 clinical trial, has been granted orphan drug status...
Read Full Article
Study reveals potential to reverse lung fibrosis using the body’s own healing technique
by Kelly Malcom, Lead Research Communicator | April 12, 2024
The most common type of lung fibrosis — scarring of the lungs -- is idiopathic, meaning
Read Full Article
Natural killer T-cell therapy to be tested in IPF patients in UK study
by Steve Bryson, PhD | March 15, 2024
UK regulators green light GRI Bio biomarker study of oral medicine GRI-0621
Read Full Article
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond
by Carmelo Sofia, Alessia Comes, Giacomo Sgalla & Luca Richeldi | Published Nov. 12, 2023
Currently approved drug treatments for idiopathic pulmonary fibrosis...
Read Full Article
IPF therapy candidate bersiporocin granted orphan drug status in EU
by Marisa Wexler, MS | February 2, 2024
Oral medication now being tested in Phase 2 clinical trial in US, Korea
Read Full Article
New FDA-cleared, AI-based tool Fibresolve may help in IPF diagnosis
by Lindsey Shapiro, PhD | January 19, 2024
Software able to recognize subtle patterns of lung scarring on imaging scans
Read Full Article
Natural plant compound berberine eased PF symptoms in mouse model
by Steve Bryson, PhD | December 22, 2023
Studies have shown compound may aid pneumonia, lung infections, COPD
Read Full Article
FDA clears GRI Bio’s Phase 2 trial of natural killer T-cell targeted therapy.
By Lindsey Shapiro, PhD | December 1, 2023
Multi-center Phase 2a biomarker study of GRI-0621 to launch this month.
Read Full Article
BMS-986278 Declared Breakthrough Therapy for Progressive PF
By Andrea Lobo | October 27, 2023
The FDA has granted breakthrough therapy designation to Bristol Myers Squibb's investigational therapy for progressive pulmonary fibrosis (PF), BMS-986278.
Read Full Article